

# **Noncancer Reference Exposure Levels for 1,4-Dichlorobenzene**

## **OEHHA Air Toxics Hot Spots Program**

**February 13, 2025**

Rima Woods, Ph.D.

Senior Toxicologist

Air Toxicology and Risk Assessment Section


Office of Environmental Health Hazard Assessment

California Environmental Protection Agency



# 1,4-Dichlorobenzene (1,4-DCB)

## Physical-Chemical Properties



- Also referred to as para-dichlorobenzene
- White crystalline solid that sublimates at ambient temperature
- Melting point: 52.7°C (127°F)
- Vapor pressure: 1.74 mm Hg (torr) @ 25°C
- Soluble in organic solvents
- Practically insoluble in water: 81 mg/L @ 25°C



# Uses and Listings

- Uses include:
  - Active ingredient in mothballs and other pesticide products
  - Component in manufacture of polyphenylene sulfide thermoplastics
  - Minor uses as oil/fuel additive and in construction products
  - Banned in California for air freshener uses
- Listed as a carcinogen under California Proposition 65 and Hot Spots programs
- Updated chronic Reference Exposure Level (REL) will supersede current chronic REL of  $800 \mu\text{g}/\text{m}^3$  (133 ppb)

# Airborne Concentrations

- In 1987 California study, detectable in 59% of the initial breath samples and 77% of the personal air samples (mainly due to indoor exposure)
- Current data on 1,4-DCB air concentrations in urban areas limited:
  - California urban ambient air monitoring up to 2007
    - Maximums of 0.4 to 3.1 parts per billion (ppb)
    - Below detection limit in most air monitoring measurements

# Toxicokinetics

- Peak tissue levels were highest in fat but declined quickly to low levels in 24 hours following inhalation exposure in rats
- Oxidized mainly by CYP450 to epoxide, followed by further oxidation to 2,5-dichlorophenol (2,5-DCP)
  - CYP2E1 main isozyme involved in the metabolism of 1,4-DCB by humans
- 2,5-DCP primarily eliminated in urine as a GSH conjugate
- 5%–16% of absorbed 1,4-DCB eliminated via urine as 2,5-DCP in 9-11 hours suggests the half-life is greater than 10 hours in humans

# Biomonitoring

## National Health and Nutrition Examination Survey (NHANES)

- Since 1980s, NHANES collected urine samples from children and adults to assess chemical exposure, including 2,5-DCP (as a biomarker for 1,4-DCB)
- Surveys suggest wide-spread non-occupational exposure to 1,4-DCB
- Levels of urinary 2,5-DCP declining over time in both adults and children

| Survey Years | Age (years) | Sample number | Geometric mean (µg/g Cr) | 50 <sup>th</sup> percentile (µg/g Cr) | 95 <sup>th</sup> percentile (µg/g Cr) |
|--------------|-------------|---------------|--------------------------|---------------------------------------|---------------------------------------|
| 1988-1994    | 20-59       | 892           | No data                  | 24                                    | 670                                   |
| 2003-2004    | All ages    | 2522          | 12.5                     | 9.29                                  | 578                                   |
| 2015-2016    | All ages    | 2650          | 3.02                     | 2.03                                  | 133                                   |

# Acute Effects of 1,4-DCB

- In humans: early occupational health surveys by Hollingsworth et al. (1956) suggest  $\geq 50$ -80 ppm - irritation of nose and eyes
- In animals: acute effects observed during first day or days of 6-8-hour exposures
  - Tremors, weakness, eye irritation @ 798 ppm in rats, guinea pig and rabbits with 8-hour exposure(s) (Hollingsworth et al., 1956)
  - Tremors and signs of sensory irritation @ 571 ppm in rats with 6-hour exposure(s) (Tyl and Neeper-Bradley, 1989)
  - Microscopic damage to liver and kidney cells @ 125 or 500 ppm with 24-hour exposure (Umemura et al., 1989, 1990)

# **Chronic/Subchronic Effects in Humans**

## **Cases of Substance Addiction**

- Numerous case reports and reviews for substance addiction to 1,4-DCB lasting months or years
  - Main finding - nonspecific damage to white matter of the brain leading to functional neurological decline (leukoencephalopathy)
  - Symptoms include limb weakness, tremor, bradyphrenia, cognitive decline
- Dermatitis also a common finding
- Exposure confirmed by presence of 1,4-DCB in blood or 2,5-DCP in urine



# Chronic/Subchronic Effects in Humans

## Occupational Exposure

- Worker exposures of 8 months to 25 years (Hollingsworth et al., 1956)
  - Spot air samples ranged from 5 to 725 ppm
  - Normal blood tests and urinalysis (no indication of liver or kidney injury), no eye damage
- Insect repellent factory worker mean exposure duration of 11.8 years, but no air sampling (Hsiao et al., 2009)
  - Increased white blood cell count and alanine aminotransferase (ALT) were observed
  - These correlated with urinary 2,5-DCP levels

# Chronic/Subchronic Effects in Humans

## Population Survey Studies in Adults

- Many studies examined associations between urinary 2,5-DCP and diseases using NHANES data
  - Limitations: Associations based on single urinary sample, multiple exposures
  - Associations with increased 2,5-DCP levels:
    - Decreased lung function
    - Increased prevalence of obesity, diabetes and metabolic syndrome
    - Higher prevalence of cancer and risk of cardiovascular disease
    - Decreased kidney function and increased vitamin D deficiency



# Chronic/Subchronic Effects in Humans

## Population Survey Studies in Children

- Associations with increased 2,5-DCP levels in children have been found for:
  - Increased prevalence of obesity and hypothyroidism
  - Earlier age of menarche in adolescent girls
- Associations of increased 2,5-DCP levels in pregnant women have been found for:
  - Decreased birth weight in male infants
  - Increase prevalence for asthma, and rashes, eczema, or hives in boys

# Chronic Effects in Animal Studies

- Two-year study in rats and mice: 0, 20, 75 and 300 ppm, 6 hours/day, 5 days/week (Aiso et al., 2005)
- Main treatment-related non-cancer findings:
  - **Liver:** Hepatocellular hypertrophy but without hepatocellular injury (male rats and male mice)
  - **Kidney:** Papilla mineralization and pelvic urothelial hyperplasia (male rats)
  - **Nasal epithelium:** Eosinophilic globules in nasal olfactory epithelium and in respiratory epithelium (female rats); respiratory metaplasia (female mice)
  - **Testis:** Mineralization (male mice)

# Chronic Effects in Animal Studies

## Noncancer pathology findings in 2-year inhalation study (Aiso et al. 2005)

| Endpoint                              | Sex<br>Species | 0 ppm             | 20 ppm | 75 ppm | 300 ppm             |
|---------------------------------------|----------------|-------------------|--------|--------|---------------------|
| Kidney: papilla mineralization        | Male<br>Rat    | 0/50 <sup>†</sup> | 1/50   | 0/50   | 41/50 <sup>**</sup> |
| Kidney: pelvic urothelial hyperplasia | Male<br>Rat    | 7/50 <sup>†</sup> | 8/50   | 13/50  | 32/50 <sup>**</sup> |
| Liver: hepatocellular hypertrophy     | Male<br>Rat    | 0/50 <sup>†</sup> | 0/50   | 0/50   | 5/50 <sup>*</sup>   |

<sup>†</sup>  $p \leq 0.05$  - positive trend; \* -  $p \leq 0.05$  and \*\* -  $p \leq 0.01$ , compared to control



# Chronic Effects in Animal Studies

## Noncancer pathology findings in 2-year inhalation study (Aiso et al. 2005)

| Endpoint                                                                         | Sex<br>Species | 0 ppm              | 20 ppm | 75 ppm | 300 ppm |
|----------------------------------------------------------------------------------|----------------|--------------------|--------|--------|---------|
| Nasal epithelium: olfactory eosinophilic globules (moderate and marked combined) | Female<br>Rat  | 27/50 <sup>†</sup> | 29/50  | 39/50* | 47/50** |
| Nasal epithelium: respiratory eosinophilic globules (slight)                     | Female<br>Rat  | 11/50 <sup>†</sup> | 10/50  | 14/50  | 38/50** |
| Nasal epithelium: respiratory metaplasia: nasal gland (slight)                   | Female<br>Rat  | 5/50 <sup>†</sup>  | 4/50   | 4/50   | 33/50** |

<sup>†</sup>  $p \leq 0.05$  - positive trend; \* -  $p \leq 0.05$  and \*\* -  $p \leq 0.01$ , compared to control



# Chronic Effects in Animal Studies

## Noncancer pathology findings in 2-year inhalation study (Aiso et al. 2005)

| Endpoint                               | Sex<br>Species | 0 ppm              | 20 ppm | 75 ppm  | 300 ppm |
|----------------------------------------|----------------|--------------------|--------|---------|---------|
| Liver: hepatocellular hypertrophy      | Male<br>Mice   | 0/49 <sup>†</sup>  | 0/49   | 0/50    | 34/49** |
| Testis: mineralization                 | Male<br>Mice   | 27/49 <sup>†</sup> | 35/49  | 42/50** | 41/49** |
| Nasal olfactory epithelium: metaplasia | Female<br>Mice | 7/50 <sup>†</sup>  | 6/50   | 2/49    | 20/50** |

<sup>†</sup>  $p \leq 0.05$  - positive trend; \*\* -  $p \leq 0.01$ , compared to control



# Developmental and Reproductive Studies in Animals

Developmental study in New Zealand white rabbits – 0, 100, 300 and 800 ppm  
6 hours/day on gestational days 6-18 (Hayes et al., 1985)

- Treatment-related increase in retroesophageal right subclavian artery in 800 ppm fetuses

| Endpoint                                                                          | 0 ppm | 100 ppm | 300 ppm | 800 ppm |
|-----------------------------------------------------------------------------------|-------|---------|---------|---------|
| Total no. of fetuses with retroesophageal right subclavian artery (total litters) | 1 (1) | 0 (0)   | 1 (1)   | 6* (5)* |

\* Significantly different from control ( $p < 0.05$ )



# Developmental and Reproductive Studies in Animals

## Two-Generation Study

Two-generation study in rats 0, 66, 211 and 538 ppm 6 hours/day, 7 days/week (Tyl and Neeper-Bradley, 1989)

- Main treatment-related findings in  $F_1$  and  $F_2$  offspring in 538 ppm group:
  - Decreased  $F_1$  and  $F_2$  pup litter size
  - Decreased  $F_1$  and  $F_2$  pup body weight and weight gain
  - Increased stillborn pups ( $F_2$ ) and pup deaths on PND 1–4 ( $F_1$  and  $F_2$ )

# Acute REL Derivation

- Developmental effects considered for acute REL derivation
- Exposure for just 1 hour during a critical period in development could result in developmental effects
  - Increased incidence of retroesophageal right subclavian artery in fetal rabbits (Hayes et al., 1985)
  - Decreased rat pup viability and body weights in a two-generation exposure study (Tyl and Neeper-Bradley, 1989)

# **Acute REL Derivation**

## **Benchmark Concentration Methodology**

- Benchmark concentration (BMC) analysis (US EPA, version 3.3.2) was performed on all adverse developmental endpoints
- The benchmark response (BMR) of 5% extra risk was used to derive the BMC for dichotomous data (pup viability).
- Continuous models with a BMR of 1 Standard Deviation (SD) of the control mean used to estimate the BMC for pup body weights.
- The BMCL (5% or 1SD) represents the 95% lower confidence limit of the BMC.

# Acute REL Derivation

Summary of BMC results for decreased body weight and viability in F<sub>1</sub> and F<sub>2</sub> rat pups from the two-generation study by Tyl and Neeper-Bradley (1989)

| Endpoint                                                 | Model           | BMC<br>(ppm) | BMCL<br>(ppm) | p-value     |
|----------------------------------------------------------|-----------------|--------------|---------------|-------------|
| F <sub>1</sub> pup decreased body weight (PND 0)         | Polynomial deg3 | 547          | 431           | 0.12        |
| F <sub>2</sub> pup decreased body weight (PND 0)         | Polynomial deg2 | 452          | 345           | 0.82        |
| F <sub>2</sub> Stillborn pups<br>(PND 0)                 | Nested          | 546          | 476           | 0.21        |
| <b>F<sub>2</sub> Stillborn + dead pups<br/>(PND 0–4)</b> | <b>Nested</b>   | <b>464</b>   | <b>288</b>    | <b>0.11</b> |

## Acute REL Derivation

- Benchmark Dose Response of 5% = 464 ppm (BMC)
- 95% lower confidence limit ( $BMCL_{05}$ ) = 288 ppm
  - 288 ppm is the Point of Departure (POD) for pup viability (and for REL derivation)
  - No time adjustment for exposure during gestation
  - Human Equivalent Concentration (HEC):  $RGDR^* = 1$  for systemic effects

\* RGDR – regional gas dose ratio

# Acute REL Derivation

- Cumulative Uncertainty Factor (UF) = 200
  - Interspecies toxicokinetic UF = 2 (for toxicokinetic differences not addressed by RGDR)
  - Interspecies toxicodynamic UF =  $\sqrt{10}$  (for lack of toxicodynamic data)
  - Intraspecies toxicokinetic ( $UF_{H-k}$ ) = 10 (for interindividual variability in toxicokinetics, including in infants, and children)
  - Intraspecies toxicodynamic ( $UF_{H-d}$ ) =  $\sqrt{10}$  (for interindividual variability in toxicodynamics, with no reason to suspect additional susceptibility of children)
- Acute REL = 288 ppm / 200  
**= 1.5 ppm (8.7 mg/m<sup>3</sup> or 8,700 µg/m<sup>3</sup>)**

# Chronic REL Derivation

- Two-year rodent 1,4-DCB exposure study by Aiso et al. (2005) used as the key study for the chronic and 8-hour RELs
- Primary organs affected in rats and mice included:
  - upper respiratory system
  - kidney
  - male reproductive system
- BMC modeling was used for treatment-related lesions
- The  $BMCL_{05}$  used as the Point of Departure (POD) for REL derivation

# Chronic REL Derivation


- Most sensitive endpoints were nasal lesions in female rats and testis mineralization in male mice

| Endpoint                                                | BMC<br>(ppm) | BMCL <sub>05</sub><br>(ppm) |
|---------------------------------------------------------|--------------|-----------------------------|
| Mineralization of testis (Male mice)                    | 5.67         | 2.29                        |
| Nasal olfactory epithelium degeneration (Female rats)   | 6.89         | 4.65                        |
| Nasal respiratory epithelium degeneration (Female rats) | 28.79        | 23.19                       |
| Kidney pelvic urothelial hyperplasia (Male rats)        | 36.10        | 29.36                       |
| Nasal gland respiratory metaplasia (Female rats)        | 111.95       | 44.35                       |
| Nasal olfactory epithelium metaplasia (Female mice)     | 151.40       | 74.77                       |
| Kidney papilla mineralization (Male rats)               | 246.91       | 91.80                       |



# Chronic REL Derivation

- BMC model fit to incidence data for nasal olfactory epithelial lesions (moderate or marked severity combined) in female rats



## Chronic REL Derivation

- Benchmark Dose Response of 5% = 6.89 ppm (BMC)
- 95% lower confidence limit ( $BMCL_{05}$ ) = 4.65 ppm
- POD = 4.65 ppm for nasal olfactory degeneration
  - Time adjustment:  
 $4.65 \text{ ppm} \times 6 \text{ hrs}/24 \text{ hrs} \times 5 \text{ days}/7 \text{ days} = 0.83 \text{ ppm}$
  - HEC:  $0.83 \text{ ppm} \times 0.2 \text{ (RGDR)} = \mathbf{0.166 \text{ ppm}}$



# Chronic REL Derivation

- Cumulative UF = 200
  - Interspecies toxicokinetic UF = 2 (for toxicokinetic differences not addressed by RGDR)
  - Interspecies toxicodynamic UF =  $\sqrt{10}$  (for lack of toxicodynamic data)
  - Intraspecies toxicokinetic ( $UF_{H-k}$ ) = 10 (for interindividual variability in toxicokinetics, including in infants, and children)
  - Intraspecies toxicodynamic ( $UF_{H-d}$ ) =  $\sqrt{10}$  (for interindividual variability in toxicodynamics, with no reason to suspect additional susceptibility of children)
- Chronic REL = 0.166 ppm / 200  
**= 0.0008 ppm (0.8 ppb, 5.0  $\mu\text{g}/\text{m}^3$ )**



## 8-Hour REL Derivation

- Based on same exposure endpoint as chronic REL
- Same POD of 4.65 ppm
- Time adjustment includes:
  - $20 \text{ m}^3 / 10 \text{ m}^3$  factor for worker exposure
- All UFs are the same as used for the chronic REL derivation
- **8-Hour REL = 1.7 ppb ( $10 \text{ } \mu\text{g}/\text{m}^3$ )**

# **Public Comments**

## **Draft Hot Spots RELs for 1,4-Dichlorobenzene**

- OEHHA released the draft document for public comment on November 29, 2024
  - Held two public workshops: December 16, 2024 and January 7, 2025
  - Public comment period ended January 13, 2025
- OEHHA received one public comment submission from CleanEarth4Kids.org

# OEHHA's Responses to Public Comment 1

*“Children are particularly vulnerable to airborne toxins like 1,4-DCB. Their respiratory systems are still developing and they have higher respiratory rates relative to their body weight, which creates a higher health risk.”*

- OEHHA's methodology explicitly considers possible differential effects on the health of infants and children, in accordance with the mandate of the Children's Environmental Health Protection Act (SB 25).
- Both acute and chronic REL derivations applied a full factor of 10 for interindividual differences in toxicokinetics, to account for infants and children
- Age-specific breathing rates and body weight are applied while conducting exposure assessment and risk characterization

## OEHHA's Responses to Public Comment 2

*“The current REL proposals ( $5 \mu\text{g}/\text{m}^3$  for chronic exposure and  $10 \mu\text{g}/\text{m}^3$  for repeated 8-hour exposure) do not sufficiently address the risk posed by higher exposure scenarios and should be further reduced to account for the significant indoor and occupational exposure documented globally.”*

- Exposure scenarios and exposure assessment are accounted for while characterizing the risk
- The Hot Spots program assesses risk to off-site workers but does not cover occupational exposures within Hot Spots facilities

## OEHHA's Responses to Public Comments 3 & 4

*“There should be more comprehensive educational campaigns about the risks of 1,4-DCB exposure, and information about safer, non-toxic alternatives.”*

- The draft TSD focuses on the scientific basis and derivation of RELs for 1,4-DCB by the inhalation route of exposure. Educational campaigns are outside the scope of this draft.

*“Additionally, there should be stronger air quality monitoring programs in vulnerable communities to identify and mitigate sources of 1,4-DCB.”*

- Risk management approaches are beyond the scope of the draft TSD for 1,4-DCB.



**Thank you!**

